IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FAVALLI, ENNIO GIULIO

FAVALLI, ENNIO GIULIO  

Dipartimento di Scienze Cliniche e di Comunità  

Mostra records
Risultati 1 - 20 di 147 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): recommendations from Italian scientific societies, patient associations and regulators 2025 Pugliano, MariateresaGualtierotti, RobertaBianchi, StefanoRosa, Silvia DeFavalli, Ennio GiulioLaterza, Claudia + Article (author) -
Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib 2025 Bellocchi, ChiaraFavalli, Ennio GiulioMaioli, GabriellaAgape, ElenaCaporali, Roberto + Article (author) -
Expanding the expanded risk score to psoriatic arthritis: any port in a storm 2025 Favalli, Ennio GiulioIngrao, LucaTrignani, GiorgiaFerrito, MatteoCincinelli, GilbertoCaporali, Roberto Article (author) -
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients 2024 Cincinelli, GilbertoMaioli, GabriellaFavalli, Ennio GiulioIngegnoli, FrancescaCaporali, Roberto + Article (author) -
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort 2024 Favalli, Ennio GiulioBiganzoli, GiacomoCincinelli, GilbertoFerrito, MatteoLuconi, EsterBiggioggero, MartinaBoracchi, PatriziaCaporali, Roberto + Article (author) -
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry 2024 Favalli E. G.Caporali R. + Article (author) -
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience 2024 Gabriella MaioliGilberto CincinelliMartina BiggioggeroRoberto CaporaliEnnio Giulio Favalli Article (author) -
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs 2024 Favalli E. G.Maioli G.Caporali R. Article (author) -
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era 2023 Cincinelli, GilbertoOrenti, AnnalisaBoracchi, PatriziaFavalli, Ennio GiulioCaporali, RobertoIngegnoli, Francesca + Article (author) -
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study 2023 Crotti C.Di Taranto R.Orsini F.Ferrito M.Favalli E. G.Caporali R. + Article (author) -
Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium” 2023 Caporali R.Favalli E. G. + Article (author) -
From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium” 2023 Caporali R.Favalli E. G. + Article (author) -
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events 2023 Favalli E. G.Cincinelli G.Germinario S.Di Taranto R.Orsini F.Maioli G.Biggioggero M.Ferrito M.Caporali R. Article (author) -
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients 2023 M. FerritoG. CincinelliR. Di TarantoE. G. FavalliR. Caporali + Article (author) -
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission 2023 Giacomelli, RobertoCaporali, RobertoBrucato, AntonioUrsini, FrancescoFavalli, Ennio + Article (author) -
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment 2023 Favalli E. G. + Article (author) -
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study 2022 Favalli, Ennio GiulioMaioli, GabriellaBiggioggero, MartinaPesce, ElisaMartinovic, MartinaGori, AndreaAbrignani, SergioCaporali, Roberto + Article (author) -
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis 2022 Gabriella MaioliRoberto CaporaliEnnio Giulio Favalli Article (author) -
Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries 2022 Favalli, Ennio G + Article (author) -
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium 2022 Favalli E. G.Caporali R. + Article (author) -